Related Experiment Videos
High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD
J Lindahl1, E Kimby, B Björkstrand
1Department of Medicine, Division of Hematology, Karolinska Institutet, Huddinge University Hospital, 141 86 Stockholm, Sweden.
Leukemia Research
|February 28, 2001
Summary
Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a T-cell lymphoma. Intensive chemotherapy with autologous stem cell transplant offers a potential treatment for aggressive cases, achieving long-term remission.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) is a lymphoproliferative disorder often associated with T-cell lymphoma.
- AILD typically presents with cytogenetic and molecular abnormalities characteristic of angioimmunoblastic T-cell lymphoma (AITL).
Observation:
- A 58-year-old male patient presented with unusually aggressive AILD, exhibiting severe hemolysis and Guillain-Barré syndrome.
- Initial CHOP therapy resulted in complete remission, but the patient relapsed within 2 months.
Findings:
- High-dose chemotherapy followed by autologous peripheral stem cell transplantation (APSCT) using CD34 selected cells proved successful in managing the relapse.
- The patient achieved complete remission and remained disease-free for 3 years post-diagnosis and 32 months post-transplant.
Implications:
- Aggressive AILD, despite its poor prognosis, may respond to intensive treatment strategies.
- Autologous peripheral stem cell transplantation (APSCT) warrants further investigation as a viable therapeutic option for refractory or relapsed AILD.